Humeta OneMarketing Platform v3

Good morning, Riya 👋

Thursday, April 24 · Generic Semaglutide · BBB Plan 2026

⚡ Daily Briefing — 4 items need attention

2 new RCT studies for Semaglutide — PIONEER-INDIA sub-group results ready

Review →

Visual Aid v2: 1 RED MLR comment flagged (Slide 4 — comparative claim)

Resolve →

MLR-approved VA content ready for Creative Studio execution

Execute →

Humeta Expert Review request pending — Strategy review booked for tomorrow 11am

View →

82%

BBB Strategy Score

↑ 14pts this session

18

Deliverables Planned

8 done · 4 in MLR · 6 pending

48h

Avg MLR Turnaround

↓ 3 days faster

₹90L

Total Year 1 Budget

213% avg ROI projected

Active Work

Generic Semaglutide BBB Plan 2026

Brand Plan · Full BBB Process · 19 Steps

In Progress

82%

18

Deliverables

4

In MLR

8

Approved

1

Creative

🎯 Humeta Expert Review (HITL)

At any stage — strategy, content, or creative — request a Humeta expert to review your work, give feedback, or book a 30-min consultation.

From ₹15K · Strategy review · Consultation · Creative critique

🔄 Insight Loop

"Rajan's patient story slides drove 3.2× higher rep engagement than MOA-first openings. Lead with patient narrative in next VA revision."

Source: Veeva CLM engagement · Q1 2026 · Confidence: High

Quick Start

📋

Brand Brief Setup

Fill the 7-step BBB brief before AI can build your plan

🎯

Brand Plan or Campaign?

Different modes, different depths — choose wisely

📅

Jump to Input Calendar

Skip to creating deliverables right away (Campaign mode)

📎

Upload Reference Material

Your medical team's VA outline, approved messaging, or brief

Brand Brief — 7-Step BBB Foundation

AI uses these 7 steps to pre-populate all 19 BBB strategy steps · Complete in 15–20 minutes

1

Product Identity & Commercial Context

Brand Name

Molecule / INN

Strength & Route

Therapy Area

MRP / Month

Launch Date

2

Disease & Market Understanding

Disease Burden (India-specific)

Geography

Primary Indication

3

Competitive Landscape & Differentiation

Primary Competitor

Other Competitors

Your Key Differentiator (in one sentence)

4

Target Audience (KSH + Patient)

Primary KSH (Prescriber)

Secondary KSH

Patient Profile

Field Force

5

Clinical Evidence & Regulatory Status

Primary Trial Data

Regulatory Status

Key Efficacy Claims (must be MLR-ready)

6

Business Objective & Success Metrics

Year 1 Revenue Target

Prescriber Target

Market Share Goal

Primary KPI

7

Brand Belief & Tone of Voice

What does this brand believe? (Single core conviction)

Tone of Voice

Emotional Territory

✅ AI Readiness: 91% — Ready to generate 17/19 BBB steps

Upload IQVIA data + CRM export to reach 100%. Humeta will pre-populate Brand Strategy, Comm. Strategy, FTE & Financials, and all 18 deliverable content frameworks.

Plan or Campaign?

These are fundamentally different modes — choose based on your objective and timeline

BRAND PLAN

Full 6–12 month strategic blueprint · Complete BBB process (19 steps) → Input calendar → Create deliverables

CAMPAIGN

Short-term focused objective · Choose BBB depth OR go direct to Input Calendar → Create deliverables

FULL BBB

📋

Brand Plan

"The full strategic journey — from market to message to media."

₹8–12L strategy fee

A complete, evidence-driven 6–12 month brand plan. You go through every BBB step in sequence — no shortcuts. Ideal for new launches, annual planning, or brand repositioning.

Your journey →

Brand Brief (7 steps) → Full BBB (19 steps) → Calendar → Create

Data Vault upload: optional but recommended

✅ All 19 BBB steps: Headroom → FTE & Financial

✅ Communication Strategy (INSIGHT + Barrier Map)

✅ FTE planning + ROI projections

✅ Full 12-month content calendar auto-generated

✅ 135 deliverable types · MLR-ready workflows

✅ Humeta Expert Review (HITL) available at every step

FLEXIBLE

🎯

Campaign

"A focused push — with or without strategy depth."

₹2–5L strategy fee

Short-term, objective-led — congress activation, competitive counter-launch, seasonal push, new indication campaign. You control the strategy depth.

Your journey — choose one →

Brand Brief → Comm. Strategy only → Calendar → Create

OR SKIP STRATEGY ENTIRELY

Input Calendar directly → Select inputs → Create immediately

Data Vault upload: optional at any stage

✅ Partial or full BBB — you decide the depth

✅ OR skip straight to Input Calendar

✅ 2–8 week campaign calendar auto-generated

✅ All deliverable types available

✅ Faster to execution — ideal for campaign bursts

— No FTE / Financial strategy module

🗄

Upload data to Vault?

Available in both modes. IQVIA, CRM, clinical data, or competitor intel can be added now or at any stage. AI uses vault data to improve accuracy across all BBB steps.

Selected: Brand Plan · Strategy fee ₹10L · Deliverables billed per rate card · Year 1 total: ₹90L (213% avg ROI)

BBB Strategy Hub — Brand Strategy

Section 1 of 3 · Steps 1–9 · Generic Semaglutide BBB Plan 2026

Step 01 · Brand Strategy

Headroom Pyramid

Market size at each patient journey stage — where is the biggest untapped opportunity?

✨ AI-generated from IQVIA vault data · Verify before MLR

GLP-1 RA Treated

8.1M

GLP-1 RA Eligible (HbA1c+BMI)

22.4M

T2DM on any therapy

54M

Diagnosed T2DM (total)

77M

Total T2DM pool (incl. undiagnosed)

101M

AI Insight

The largest headroom sits at the affordability barrier — 14.3M patients are eligible, prescribed GLP-1 RA, but cannot fill. This is your primary leverage point.

Source: IQVIA India Anti-diabetic Audit 2024 · IDF Atlas 10th Ed 2023 · ICMR-INDIAB 2023

Strength Meter

86

Evidence Quality★★★★★

Source Coverage★★★★★

Logic Coherence★★★★☆

Regulatory RiskLow

🎯 Humeta Expert Review

Get a Humeta strategy expert to review this section and give recommendations.

Upload Reference

Attach existing material for AI to refer

Sources

1. IQVIA India MAT Dec 2024
2. IDF Diabetes Atlas, 10th Ed
3. ICMR-INDIAB National Survey
4. CDSCO Drug Register 2025

BBB Strategy Hub — Communication Strategy

Section 2 of 3 · Steps 10–14 · INSIGHT Framework + Barrier Map + Key Messages

Step 13 · Communication Strategy

Creative Idea — I.N.S.I.G.H.T Framework

Drilling from individual observation to a universal human truth — and from truth to a brand idea

✨ AI-generated from Steps 5, 6 & 9 · Brand Strategy inputs

I

Individual KSH Insight

"I want to prescribe GLP-1 RA earlier — but ₹11K/month means my patient won't fill it. I need an option I can actually write."

N

Narrative / Cultural Context

India's middle class achieves the world on sheer will — but health care shouldn't be another ceiling. The nation that democratised insulin should lead GLP-1 access too.

S

Systemic Driver

Price is the system that blocks doctors from acting on their clinical conviction. The drug isn't the barrier — the bill is.

I.G — Guide: The Core Killer Insight

"When a doctor writes Ozempic, they're prescribing hope. When the patient can't afford it, that hope is denied. Generic Semaglutide: prescribed hope at an Indian price."

H — Hook: The Big Idea

"Same Medicine. Different Price. Different Life."

Show identical clinical outcomes in two Indian patients — one on Ozempic, one on Generic Sema. Same HbA1c. Same weight. Different price tag. Same life restored.

T

Translation — How the idea comes alive across touchpoints

VA: Rajan's 16-week journey · LBL: SUSTAIN data infographic · AV: 'Rajan Effect' 3-part series (Hindi + 3 regional) · Social: #AffordableHope · Congress: Doctor + patient at pharmacist counter moment

B1 — Economic Barrier (Affordability)

B1 — Economic

Ozempic at ₹11K/month excludes 90% of eligible patients — cost is the conversation-stopper at the pharmacist counter

Engagement Imperative: Make affordability the brand's clinical advantage — not a footnote, not an apology

Branded Zone

Affordability comparison card: ₹1,800 vs ₹11,200 (60% saving visual)

EMI simulator: '₹60/day vs a coffee'

PSP enrolment script in Visit 2

Neutral / CME Zone

CME: 'Cost of uncontrolled T2DM' — dialysis vs GLP-1 cost-benefit

KOL roundtable: 'Access-first prescribing'

Digital / Patient

#AffordableHope patient community

WhatsApp bot: 'How much could you save?'

OTT pre-roll: pharmacist counter moment

Strength

78

Message 01 — Brand Delivers

Clinical Proof

Same 1.5–1.8% HbA1c reduction as innovator, backed by SUSTAIN Phase 3 data.

Message 02 — Helps Achieve

The Double Win

One weekly injection controls both sugar and weight — measurable in 16 weeks.

Message 03 — Accessible

₹1,800/month

60% below Ozempic. Your patient doesn't choose between heart and wallet.

🎯 Humeta Expert Review

Request a 30-min strategy consultation on your comm. strategy and insight framework.

BBB Strategy Hub — FTE & Financial Strategy

Section 3 of 3 · Steps 15–19 · Engagement Plans + Tactical + Calendars

240

Total FTEs

₹90L

Year 1 Investment

213%

Avg ROI

5,000

Target Physicians

85%

Coverage Target

FTE Breakdown (Step 15A)

180

Medical Reps

40

Specialty Reps

12

MSLs

8

KAMs

Out-of-Clinic Plan (Step 15B)

National Congresses (RSSDI, API, CSI, DIPSI)4/yr · ₹24L

CME Events (Tier 2/3)100/yr · ₹20L

KOL Round Tables12/yr · ₹12L

Patient Camps144 camps · ₹8L

Step 16 — Tactical Plans per Leverage Point

LP	KSH	Behavioural Objective	Tactic	Cost	ROI
A — Origination	GPs Tier 2	GP identifies HbA1c>7.5+BMI>27 as GLP-1 RA signal	100 CME events in Tier 2/3 — GLP-1 RA class education	₹22L	180%
C — Class Choice	Endo / Diabeto	GLP-1 RA becomes preferred 2nd line at HbA1c + weight failure	SUSTAIN/PIONEER detailing + CVOT data + KOL position paper at RSSDI	₹18L	200%
D — Brand Choice	Endo / Cardio	Generic Sema = default GLP-1 RA choice vs Ozempic	BE data + WHO-GMP + Affordability calculator + Rajan's Story LBL	₹28L	220%
E — Fulfilment	Pharmacy / Hospital	Generic Sema in top 200 hospitals + 2,000 pharmacies	KAM-led formulary drive + retail pharmacist connect (20 cities)	₹8L	250%
F — Adherence	Patients	80% patient retention at 6 months via PSP	PSP + Generic Sema Tracker App + Rajan's 16-week video + WhatsApp	₹14L	190%

Total Year 1 Investment ₹90L 213% avg ROI

Step 17–19 — Engagement Calendars

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

In-Clinic (Step 17)

VA Detailing — Full SUSTAIN

VA

LBL — Rajan's Story Series

LBL

Affordability Comparison Card

✓

Congress / CME / KOL (Step 18)

National Congresses (4)

CON

CME Events (100/yr Tier 2/3)

8

9

8

KOL Round Tables (12/yr)

RT

Digital (Step 19)

LinkedIn — Weekly HCP content

4x

Patient AV 'Rajan Effect'

EP1

EP2

EP3

Generic Sema Tracker App

PSP

Data Vault

All uploaded data — IQVIA, CRM, clinical, competitor intel, reference materials · Upload anytime, use anywhere

All (8) Market Data (3) Clinical (2) Reference Material (2) MLR Approved Messaging (1)

📊

IQVIA India Anti-Diabetic Audit MAT Dec 2024

Excel · 4.2 MB · Uploaded Apr 18 · Used in 14 BBB steps

Market Data

📄

SUSTAIN 1–9 Trial Summary — Meta-analysis

PDF · 2.1 MB · Uploaded Apr 15 · Used in Clinical Evidence steps

Clinical

📋

Medical Team VA Outline — Generic Sema v1.pptx

PPT · 3.8 MB · Uploaded Apr 20 · Reference for Content Studio

Reference

✅

MLR-Approved Messaging Deck — Generic Sema 2025.pdf

PDF · 1.4 MB · Uploaded by Medical Affairs · Apr 22 · MLR Pre-approved claims

MLR Approved

📊

Veeva CRM Segmentation Export Q1 2026

CSV · 1.1 MB · Uploaded Apr 16 · Used in KSH analysis

Market Data

Execution Hub — Input Calendar

Manage deliverables, budgets, and timelines · Campaign mode: select inputs and start creating directly

May–June 2026 — Active Deliverables

Visual Aid — Rajan's Story v2

10 slides · Endocrinologist · In-clinic detailing

🔍 In MLR

SUSTAIN data + Rajan patient arc + Affordability panel. Big idea: 'Same Medicine. Different Price. Different Life.'

Due: May 15₹3.8L

LBL — Rajan's Story Patient Series

4-page fold · Patient-facing · Leave-behind

✓ Approved

Top 3 messages + HbA1c chart + Dosing guide + PSP QR code. Affordability comparison visible.

Due: May 1₹85K

AV — 'Rajan Effect' Episode 1

2-min · Hindi + 3 regional · YouTube / WhatsApp

🎨 Creative Studio

MLR approved. Moving to Creative Studio — storyboard, voiceover, animation direction.

Due: Jun 1₹8.5L

CME Deck — GLP-1 RA Masterclass

30 slides · KOL-led · Tier 2 cities

⏳ In Progress

GLP-1 mechanism + SUSTAIN 1–9 meta-analysis + Indian T2DM context + 3 case studies.

Due: Jun 15₹2.1L

+

Add deliverable

135 types available

12-Month Content Calendar — Edit Inline

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

VA — Rajan's Story v2

VA

LBL — Patient Series

LBL

AV — Rajan Effect

EP1

EP2

EP3

LinkedIn Posts

4x

Monthly Cost

₹8.2L

₹6.4L

₹9.1L

₹7.3L

₹8.8L

₹9.6L

₹6.2L

₹7.8L

₹5.4L

₹7.1L

₹6.9L

₹7.2L

Visual Aid — Rajan's Story v2

In MLR 10 slides · Endocrinologist · ₹3.8L

Slides (10)

Sources

Options

MLR (1)

Sources — Opening Slide

1. IQVIA India MAT Dec 2024
2. IDF Diabetes Atlas, 10th Ed 2023
3. ICMR-INDIAB National Survey 2023
4. SUSTAIN-6 · NEJM 2016

MLR Flag

🔴 Dr. Mehta (Medical) · Slide 4

'Superior glycaemic control' is comparative — needs head-to-head citation or reword to 'effective glycaemic control'.

Accept & Revise

Reply

Reference Material

📋

Medical Team VA Outline.pptx

3.8 MB · Uploaded Apr 20

AI is referencing this slide outline to maintain structure and include all medically-required sections.

Select a slide to see version options

MLR Review

Medical · Legal · Regulatory · Covers both Content Studio and Creative Studio submissions

Content Studio MLR 1 RED

Creative Studio MLR 1 AMBER

1

RED — Must Change

Blocks proceed to Creative Studio

2

AMBER — Consider

Can decline with justification

3

GREEN — Approved

No action required

✅

MLR Pre-approved Messaging Available

Medical Affairs uploaded "MLR-Approved Messaging Deck — Generic Sema 2025.pdf" — AI is using pre-approved claims in all content generation. Reviewers can add more.

Open Comments — Visual Aid v2

🔴 Dr. Mehta (Medical) · Slide 4 — MOA Claims

"'Superior glycaemic control' is a comparative claim. Must have head-to-head citation or reword to 'effective glycaemic control'. Regulatory requirement — cannot approve as-is."

✓ Accept & Revise

✏️ Suggest Edit

↩ Reply

🟡 Adv. Krishnan (Legal) · Slide 7 — Affordability

"Price comparison (₹1,800 vs ₹11,200) must carry disclaimer: 'Prices indicative; may vary by retailer.' Legal advises visible footnote."

✓ Accept

✏️ Suggest Edit

✗ Decline

🟡 Ms. Verma (Regulatory) · Slide 10 — Dosing

"Add CDSCO-mandated AE statement: nausea, pancreatitis, MTC contraindication must appear on dosing slide."

✓ Accept

✏️ Suggest Edit

✗ Decline

✅ Once all RED resolved → click "All Resolved → Creative Studio" above. Content locks and moves to Creative Studio execution.

Reviewer Status

Dr. S. Mehta

Medical Reviewer

Submitted

Adv. Krishnan

Legal Reviewer

Submitted

Ms. Verma

Regulatory Reviewer

Reviewing

26h / 48h target

Share Review

Reviewers get a clean read-only link. They add comments, suggest edits, or upload approved messaging directly. Changes integrate with one click.

Visual Aid — Rajan's Story v2

Creative Execution

Choose Input Type

Or let Humeta AI decide what will work best for this objective

🤖 Let Humeta Decide

AI chooses format, size, tone, media

📄

Visual Aid (VA)

10-slide CLM / print VA for in-clinic

📋

LBL / Brochure

4-page fold · Leave-behind

🎬

AV / Video

60s / 2-min animated or live · Choose screen size, voice, subtitles

📱

Social / Digital

LinkedIn post, emailer, banner

🎓

CME Deck

KOL-narrated slide deck

🗂

Detailing Aid

Rep-narrated flip chart or iPad aid

🖼

Congress Poster

A0 / A1 · Data-heavy scientific poster

📊

Infographic

Single-page data visual for HCPs

Style Direction

Clinical-warm. Evidence-first, human-second.

Colour Palette

Deep navy + Saffron accent + White

Image Style

Indian patient photography + AI-generated data visuals

Output Format

Print-ready PDF + Veeva CLM HTML5

Big Idea

"Same Medicine. Different Price. Different Life."

Tagline

"The science of Sema. The heart of India."

Executed Slides — Per-Page Creator & MLR Approval Required

All Slides

🎯 Expert Creative Review

Humeta creative director reviews your execution and gives specific visual and messaging feedback.

⚡ Adapt This Deliverable

Convert this VA into another format — LBL, CME deck, emailer, congress poster, or video storyboard. AI carries all approved content.

Page Approval Status

Slide 01✓ Creator + MLR

Slide 02🔴 MLR Flagged

Slides 03–07✓ Creator + MLR

Slides 08–10⏳ Awaiting MLR

6/10 fully approved · Cannot deploy until 10/10

Deployment Hub

Push creative-executed, MLR-approved deliverables to all channels

✅

Ready to Deploy: Visual Aid — Rajan's Story v2 · All 10 pages approved

Creator approved · MLR approved · Content MLR resolved · Creative MLR resolved · Apr 24, 2026

Choose Deployment Channels

💊

Veeva CLM

Rep tablet deployment · 180 MRs · Auto-sync to Veeva Vault · HTML5 package

Your Veeva licence required

📬

Email Direct

2,000 target HCPs · Your contact list · HTML5 emailer · Open rate tracking

Free · Included in plan

💼

HCP page · 50K follower target · Organic + paid · Carousel adapted automatically

Organic free · Paid optional

📱

WhatsApp Broadcast

Rep WhatsApp lists · Patient PSP groups · Formatted for mobile · Compliance-approved

Included in plan

🏥

CRM / Salesforce

Push to rep CRM activity · Auto-log detailing material · Track physician exposure

CRM integration required

📄

Print-Ready PDF

High-res PDF for print vendors · Bleed marks included · CMYK colour profile

Free · Download instantly

🎥

OTT / YouTube Pre-roll

AV deliverables auto-formatted · 15s / 30s cuts · Doctor targeting via Google Health

Google Ads account required

🌐

Brand Website / iRep

HCP portal integration · iRep module push · Gated or public content options

Included in plan

🎪

Congress / Event

Booth panels · podium packs · Print-ready · A0/A1 poster export for RSSDI / API

Included in plan

Recent Deployments

✅

LBL — Patient Story Q1 · Veeva CLM

Deployed to 180 MRs · Apr 22 · 142 first opens recorded

Live

✅

LinkedIn Post Series (8 posts) · Organic

Published Apr 18–22 · 4,200 HCP impressions · 186 engagements

Live

⏳

Visual Aid — Rajan's Story v2 · Pending Creator Final Approve

MLR cleared · 1 slide pending creator stamp · Cannot deploy until 10/10

Pending

Measurement

Performance tracking across all active deliverables · April 2026

3.2×

Avg Rep Engagement (CLM)

↑ vs MOA-first opens

68%

MLR First-Pass Rate

↑ 12pts vs last quarter

48h

Avg MLR Turnaround

↓ 72h saved

213%

Projected ROI

Year 1 full projection

Deliverable Performance

VA — Rajan's Story3.2× engagement

LBL — Patient Series74% leave-rate

LinkedIn Posts4,200 HCP impressions

MLR Efficiency

Total MLR cycles6

Avg cycles per deliverable1.3

RED comments (content)2

RED comments (creative)0

Avg resolution time18 min

Insight Loop

Performance signals feeding back into strategy improvements

Active Signals

📊 CLM Signal

"Rajan's Story slides drove 3.2× higher rep engagement than MOA-first openings. Recommend leading with patient narrative in next VA revision — especially for GPs."

Veeva CLM engagement · Q1 2026 · Confidence: High · Affects: Step 12 Storytelling

💊 Prescription Signal

"Affordability comparison card is being left-behind in 74% of Tier 2 visits. Price messaging is resonating stronger in semi-urban vs urban market."

MR field reports + CRM · Mar–Apr 2026 · Confidence: Medium